Hyperacidity/GERD/ulcers

Gastroprotective Effects of PPIs, H2RAs Compared in Patients on DAPT

By July 03, 2018

For this study, researchers searched several large databases (from 1980 to 2016) for randomized, controlled trials (RCTs) that compared clinical outcomes in patients on DAPT taking PPIs or H2RAs.

Pharmacologic Tx Should Be Used Sparingly for Reflux in Preemies

June 19, 2018

There is a lack of evidence for efficacy of pharmacologic agents and emerging evidence of significant harm; consequently, these agents should be used sparingly, if at all.

DDW: Psych Disorders Make GERD Hard to Dx by Symptoms Alone

June 06, 2018

The researchers found that the mean DeMeester score was 44 ± 33 for GERD+ and 7 ± 4 for GERD−. For GERD+ and GERD−, the mean HADS scores for anxiety (8 for both; P=0.2) and depression (5 and 6, respectively; P=.3) did not differ significantly.

Review Provides Recommendations for Effective PPI Discontinuation

By May 24, 2018

According to the review, a substantial number of patients can effectively decrease or completely discontinue use of PPIs, as often these agents are prescribed without an appropriate reason.

Wearable Acid Reflux Device Now Available Over-the-Counter

By May 02, 2018

The Reza Band is worn around the neck while sleeping and applies slight external pressure to the cricoid cartilage area, which increases the internal pressure of the upper esophageal sphincter (UES).

GI Safety Compared for NSAIDs in Patients With Arthritis

By April 19, 2018

The randomized, double-blind, controlled trial (N=24,081) included patients with rheumatoid arthritis or osteoarthritis who required chronic NSAID treatment.

OTC Heartburn Treatment Available in New Orally Disintegrating Tablets

By April 11, 2018

Omeprazole ODT utilizes MelTech technology that allows the tablet to dissolve in the mouth without water.

Acid suppression and antibiotic use in infancy linked to allergic disease

April 11, 2018

Use of histamine 2 receptor antagonists (H2RA) or proton pump inhibitors (PPIs) during the first 6 months of life was associated with increased risk of allergic disease and asthma.

Antibiotics, Acid-Suppressive Meds Tied to Allergic Disease

April 03, 2018

The researchers found that 7.6% of included children were prescribed a histamine-2 receptor antagonist (H2RA), 1.7 percent a proton pump inhibitor (PPI), and 16.6% an antibiotic during the first 6 months of life.

Wearable System Provides 24-Hour Ambulatory GI Monitoring

By March 22, 2018

The wearable system was found to work as well as more invasive methods.

FDA Clears New <i>H. pylori</i> Testing Option for Pediatric Patients

By March 13, 2018

The result comparisons found an overall agreement in the pre-therapy cohort between the breath test and the reference biopsy result of 98.3% (95 CI: 95.2%-99.7%).

Review: Managing Patients With Refractory Heartburn

By February 01, 2018

Patients with functional heartburn display similar symptoms seen in GERD and most often complain of a burning retrosternal discomfort. Once the underlying cause of a patient's refractory heartburn is determined, appropriate therapy can be initiated.

Links Between Bacterial Infection and Gallbladder Disease Investigated

December 18, 2017

Among participants ≤45 years in the H. pylori-positive group, the prevalence of gallstones was lower than in the H. pylori-negative group (odds ratio, 0.653).

PPI Use May Up Gastric Cancer Risk Even After <i>H. Pylori</i> Eradication Tx

November 02, 2017

Results showed that PPI use correlated with elevated risk of GC (hazard ratio, 2.44; 95% confidence interval, 1.42 to 4.2), while histamine-2 receptor antagonist use was not associated with increased risk (hazard ratio, 0.72; 95% confidence interval, 0.48 to 1.07).

Proton Pump Inhibitor Use Linked to Two Distinct Dermatological Reactions

By October 18, 2017

The case involved a 32-year-old male who was prescribed pantoprazole after initially presenting with dyspepsia-like symptoms.

PPI Use and First-Time Stroke, MI: What's the Link?

October 18, 2017

After adjustment for age, sex, comorbidities, and concomitant medications, the rates of ischemic stroke and MI were significantly increased with current PPI exposure (hazard ratios, 1.13 and 1.31).

PPI Effectiveness Compared for Erosive Esophagitis Management

By September 28, 2017

The researchers chose endoscopic healing rates (at 4 and 8 weeks) as the primary efficacy outcome.

Best Practice Recs for <i>H. pylori</i> Treatment Reviewed

By September 22, 2017

The authors stated that the recommended approach should be based on local and individual antibiotic resistance patterns.

PPIs Should Be Focus for Deprescribing, Says New Research

September 20, 2017

From 2000 to 2016 there was little change in the extent of appropriate PPI use reported in 34 international studies. Patient-centered deprescribing, academic detailing, educational programs, and safety notifications were interventions for addressing inappropriate use.

Diet May Be as Effective as PPIs in Reducing Reflux Symptoms

By September 07, 2017

In this retrospective study, researchers from New York Medical College, Valhalla, NY, compared the efficacy of diet-based treatment consisting of alkaline water (pH >8.0) and plant-based Mediterranean-style diet vs. the conventional PPI approach.

Prescription Strength Acid-Suppressing Agent Soon to Be Unavailable

By September 05, 2017

Both the 150mg and 300mg strengths are available as a generic; the 150mg strength is also available over-the-counter.

Study Aims to "Set the Record Straight" on PPIs and Dementia

By July 20, 2017

After multivariable adjustment - which included duration of chronic medical conditions - a modest statistically significant association was only seen for psychomotor speed and attention.

Bismuth-Based Quad Tx Compared to Levofloxacin Triple Tx for <i>H. pylori</i> Infection

July 14, 2017

Addition of bismuth subcitrate to levofloxacin-based triple tx no more effective for H. pylori infection

Proton Pump Inhibitor Use May Up Death Risk

By July 05, 2017

The authors found that compared to the use of H2RA therapy, patients initiated on PPI therapy had a 25% increased risk of death (hazard ratio [HR] 1.25, 95% CI: 1.23-1.28).

Do PPIs Increase the Risk of Dementia?

By June 22, 2017

The data indicated continuous PPI use was tied to a reduced risk of cognitive function decline vs. never use (hazard ratio [HR] 0.78, 95% CI: 0.66-0.93; P=0.005).

Nephron Pharma Responds to Sodium Bicarbonate Shortage

By June 22, 2017

Nephron Pharmaceuticals has joined the effort to abate the nationwide shortage of Sodium Bicarbonate 8.4% by tripling its production of the injectable syringes.

Sodium Bicarbonate Syringe Availability Announced in Response to Shortage

By June 20, 2017

QuVa will be supplying Sodium Bicarbonate PF 8.4% to both current and new customers.

<i>H. Pylori</i> Treatment May Also Improve This Skin Condition

May 08, 2017

Significant decrease in most criteria of rosacea Duluth score in patients cured of H. pylori infection

AGA: Best Practices for Prescribing PPIs

By April 07, 2017

While the benefits of treatment should be weighed against the risks on an individual basis, the AGA has provided recommendations to help clinicians make treatment decisions with regards to PPI use.

PPI Use Significantly Increases Pneumonia Risk in Dementia

March 30, 2017

A retrospective cohort study looked at 786 patients with dementia and new PPI usage and 786 matched patients with dementia without PPI usage.